The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Mar 31, 2025 • 1h 19min
Ep176: David Roblin on Building a TechBio Company
David Roblin, CEO of Relation Therapeutics, delves into the revolutionary use of multi-omic tools and machine learning in drug discovery. He discusses the power of collaboration within London's biotech scene and shares insights from his journey from clinical medicine to the pharmaceutical industry. Roblin highlights the importance of teamwork, the impact of non-coding DNA on disease understanding, and how AI integration is transforming drug development. His fascinating perspective on interdisciplinary science and partnerships offers a glimpse into the future of biopharma innovation.
Mar 16, 2025 • 1h 11min
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Andy Scharenberg, Co-founder and CEO of Umoja Biopharma, is advancing in vivo CAR-T cell therapies to make life-saving treatments more accessible. He talks about the challenges and breakthroughs in CAR T-cell treatments, including the transformative possibilities of gene therapies. Scharenberg reflects on his journey from medicine to molecular innovation and highlights the importance of collaboration in tackling complex immune disorders. He also shares exciting developments aimed at revolutionizing cancer treatment and enhancing patient outcomes.
Mar 3, 2025 • 1h 7min
Ep174: Najat Khan on the TechBio Movement
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
Feb 11, 2025 • 58min
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
Jan 27, 2025 • 1h 21min
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Jan 13, 2025 • 1h 2min
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
Jan 2, 2025 • 60min
Ep170: David Schenkein on Investing in the Future of Biotech
David Schenkein, a general partner at GV and a seasoned hematologist, shares insights from his journey in biotech. He discusses the importance of company culture and how his diverse background shaped his investment philosophy. Schenkein emphasizes embracing failure as a vital part of innovation and reveals the interplay between AI and drug discovery. He reflects on his transition from CEO to venture capitalist, underlining the need for diverse strategies in investing. His vision focuses on patient outcomes and the transformative potential of biotech advancements.
Dec 11, 2024 • 1h 2min
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Nov 25, 2024 • 1h
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
Nov 6, 2024 • 1h 11min
Ep167: Leslie Williams on transfer RNA therapies
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.
